Volume 137, Issue 6, Pages 2010-2017 (December 2009) Long-term Probability of and Mortality From De Novo Malignancy After Liver Transplantation Kymberly D.S. Watt, Rachel A. Pedersen, Walter K. Kremers, Julie K. Heimbach, William Sanchez, Gregory J. Gores Gastroenterology Volume 137, Issue 6, Pages 2010-2017 (December 2009) DOI: 10.1053/j.gastro.2009.08.070 Copyright © 2009 AGA Institute Terms and Conditions
Figure 1 Nonskin malignancy by underlying liver disease diagnosis. AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; Crypt, cryptogenic cirrhosis; FHF, fulminant hepatic failure; HBV, hepatitis B virus; HCV, hepatitis C virus; Malig, malignancy; Metab, metabolic disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis. *3 cases with ALD and HCV included in ALD category. Gastroenterology 2009 137, 2010-2017DOI: (10.1053/j.gastro.2009.08.070) Copyright © 2009 AGA Institute Terms and Conditions
Figure 2 (A) and (B) Probability of developing de novo nonskin malignancy by underlying disease. 1a, hematologic malignancy, 1b, solid organ malignancy. Gastroenterology 2009 137, 2010-2017DOI: (10.1053/j.gastro.2009.08.070) Copyright © 2009 AGA Institute Terms and Conditions
Figure 3 Probability of site-specific malignancies. GI, gastrointestinal; GU, female genitourinary; OP, oropharyngeal/laryngeal. Gastroenterology 2009 137, 2010-2017DOI: (10.1053/j.gastro.2009.08.070) Copyright © 2009 AGA Institute Terms and Conditions